209 related articles for article (PubMed ID: 33420377)
21. Reactive Oxygen Species Drive Proliferation in Acute Myeloid Leukemia via the Glycolytic Regulator PFKFB3.
Robinson AJ; Hopkins GL; Rastogi N; Hodges M; Doyle M; Davies S; Hole PS; Omidvar N; Darley RL; Tonks A
Cancer Res; 2020 Mar; 80(5):937-949. PubMed ID: 31862780
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
23. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).
Imbert-Fernandez Y; Clem BF; O'Neal J; Kerr DA; Spaulding R; Lanceta L; Clem AL; Telang S; Chesney J
J Biol Chem; 2014 Mar; 289(13):9440-8. PubMed ID: 24515104
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
26. PFKFB3 promotes endotoxemia-induced myocardial dysfunction through inflammatory signaling and apoptotic induction.
Tian W; Guo HS; Li CY; Cao W; Wang XY; Mo D; Hao XW; Feng YD; Sun Y; Lei F; Zhang HN; Zhao MG; Li XQ
Toxicol Appl Pharmacol; 2019 Apr; 368():26-36. PubMed ID: 30776389
[TBL] [Abstract][Full Text] [Related]
27. Blockage of glycolysis by targeting PFKFB3 suppresses the development of infantile hemangioma.
Yang K; Qiu T; Zhou J; Gong X; Zhang X; Lan Y; Zhang Z; Ji Y
J Transl Med; 2023 Feb; 21(1):85. PubMed ID: 36740704
[TBL] [Abstract][Full Text] [Related]
28. Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Zhu Y; Lu L; Qiao C; Shan Y; Li H; Qian S; Hong M; Zhao H; Li J; Yang Z; Chen Y
Oncogene; 2018 May; 37(21):2837-2849. PubMed ID: 29511345
[TBL] [Abstract][Full Text] [Related]
29. TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
Rodríguez-García A; Samsó P; Fontova P; Simon-Molas H; Manzano A; Castaño E; Rosa JL; Martinez-Outshoorn U; Ventura F; Navarro-Sabaté À; Bartrons R
FEBS J; 2017 Oct; 284(20):3437-3454. PubMed ID: 28834297
[TBL] [Abstract][Full Text] [Related]
30. Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Ray U; Roy D; Jin L; Thirusangu P; Staub J; Xiao Y; Kalogera E; Wahner Hendrickson AE; Cullen GD; Goergen K; Oberg AL; Shridhar V
J Exp Clin Cancer Res; 2021 Jun; 40(1):182. PubMed ID: 34082797
[TBL] [Abstract][Full Text] [Related]
31. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
[TBL] [Abstract][Full Text] [Related]
32. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
33. AICAR enhances the cytotoxicity of PFKFB3 inhibitor in an AMPK signaling-independent manner in colorectal cancer cells.
Yan S; Yuan D; Li Q; Li S; Zhang F
Med Oncol; 2021 Nov; 39(1):10. PubMed ID: 34761330
[TBL] [Abstract][Full Text] [Related]
34. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.
Feng Y; Wu L
Biochem Biophys Res Commun; 2017 Feb; 483(2):897-903. PubMed ID: 28082200
[TBL] [Abstract][Full Text] [Related]
35. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
36. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Bando H; Atsumi T; Nishio T; Niwa H; Mishima S; Shimizu C; Yoshioka N; Bucala R; Koike T
Clin Cancer Res; 2005 Aug; 11(16):5784-92. PubMed ID: 16115917
[TBL] [Abstract][Full Text] [Related]
39. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis.
Li FL; Liu JP; Bao RX; Yan G; Feng X; Xu YP; Sun YP; Yan W; Ling ZQ; Xiong Y; Guan KL; Yuan HX
Nat Commun; 2018 Feb; 9(1):508. PubMed ID: 29410405
[TBL] [Abstract][Full Text] [Related]
40. The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.
Reddy MM; Fernandes MS; Deshpande A; Weisberg E; Inguilizian HV; Abdel-Wahab O; Kung AL; Levine RL; Griffin JD; Sattler M
Leukemia; 2012 Mar; 26(3):481-9. PubMed ID: 21860432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
